Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery

Pharmazie

Volumn 65, Issue 8, 2010, Pages 585-587

  Hu, LianDong ^a   Jia, Yanhong ^a   Ding, Wen ^a  

^a HEBEI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; SOLID LIPID NANOPARTICLE; AEROSOL; ANTINEOPLASTIC ANTIBIOTIC; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG RELEASE; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NANOENCAPSULATION; NEBULIZATION; NONHUMAN; PARTICLE SIZE; RAT; ZETA POTENTIAL; AEROSOL; ANIMAL; CELL SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG FORMULATION; ELECTROCHEMISTRY; LUNG; METABOLISM; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

AEROSOLS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; ELECTROCHEMISTRY; EPIRUBICIN; LUNG; MALE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77955874390     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.0023     Document Type: Article

References (17)

1. Arcamone F, Penco S, Vigevani A, Redaelli S, Franchi G, Di Marco A, Casazza AM, Dasdia T, Formelli F, Necco A, Soranzo C (1975) Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone J Med Chem 18: 703-707.
2. Bi R, Shao W, Wang Q, Zhang N (2009) Solid lipid nanoparticles as insulin inhalation carriers for enhanced pulmonary delivery. J Biomed Nanotechnol 5: 84-92.
3. Casazza AM (1979) Experimental evaluation of anthracycline analogs. Cancer Treat Rep. 63: 835-844.
4. Coukell AJ, Faulds D (1997) Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties andtherapeutic efficacy in the management of breast cancer. Drugs 53: 453-482.
5. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, Zhang Q, He Q, Zhang Z (2008) Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 356: 333-344.
6. Mehnert W, Mader K (2001) Solid lipid nanoparticles production, characterization and applications, Adv Drug Deliv Rev 47: 165-196.
7. Mendes, PJ, Pinto, JF, Sousa, JM (2007) A non-dimensional functional relationship for the fine particle fraction produced by dry powder inhalers. Aerosol Sci. 38: 612-624.
8. Müller RH, Lucks JS (1996) Arzneistoffträger aus festen Lipidteilchen, Feste Lipidnanosphären (SLN). Eur Pat 0605497.
9. Pison U, Welte T, Giersig M, Groneberg DA (2006) Nanomedicine for respiratory diseases. Eur J Pharmacol 533: 341-350.
10. Plosker GL, Faulds D (1993) Epirubicin. A review of itspharmacodynamic and pharmacokinetic properties, and ther-apeutic use in cancer therapy. Drugs 45: 788-856.
11. Robert J (1993) Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs 45 [Suppl 2]: 20-30.
12. Robert J (1994) Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet 26: 428-438.
13. Sakagami M (2006) In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 58: 1030-1060.
14. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R (2006) Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 58: 996-1008. (Pubitemid 44709266)
15. Schwarz C, Mehnert W (1999) Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J Microencapsul 16: 205-213. (Pubitemid 29099602)
16. Shoyele SA, Cawthorne S (2006) Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev 58: 1009-1029.
17. Sung JC, Pulliam BL, Edwards DA (2007) Nanoparticles for drug delivery to the lungs. Trends Biotechnol 25: 563-570.